Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Meet Our Editorial Board Member: promotion: free to download

Volume:16   Issue:3
Pp: 199-199
Ingunn Holen
DOI: 10.2174/156800961603160206121939

Order Reprints Order Eprints

Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy

Volume:16   Issue:3
Pp: 200-208
Martin Andrs, Jan Korabecny, Eugenie Nepovimova, Daniel Jun, Zdenek Hodny and Kamil Kuca
DOI: 10.2174/156800961603160206122927

Order Reprints Order Eprints

Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models

Volume:16   Issue:3
Pp: 226-237
Cristina P.R. Xavier, Milica Pesic and M. Helena Vasconcelos
DOI: 10.2174/1568009616666151113120705

Order Reprints Order Eprints

Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer

Volume:16   Issue:3
Pp: 249-260
A. Nogueira-Rodrigues, A.C. Melo, G. Werutsky, A.H.I. Garces and C.G. Ferreira
DOI: 10.2174/1568009616666151118115018

Order Reprints Order Eprints

Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma

Volume:16   Issue:3
Pp: 261-274
Marilù Fanelli, Claudia Maria Hattinger, Serena Vella, Elisa Tavanti, Francesca Michelacci, Beth Gudeman, Daryl Barnett, Piero Picci and Massimo Serra
DOI: 10.2174/1568009616666151106120434

Order Reprints Order Eprints